United States

Sosei Group Corp (4565.T)

4565.T on Tokyo Stock Exchange

25 Aug 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for 4565.T


Sosei Group Corporation is a holding company primarily engaged in the biopharmaceutical business. The Company is mainly involved in the research, development and sale of pharmaceutical drugs, including NVA237 and QVA149, used for chronic obstructive pulmonary disease; SO - 1105, used for oral thrush. As of March 31, 2013, the... (more)


Beta: 1.36
Market Cap(Mil.): ¥297,668.50
Shares Outstanding(Mil.): 16.89
Dividend: --
Yield (%): --


  4565.T Industry Sector
P/E (TTM): 28.43 36.75 36.56
EPS (TTM): 619.77 -- --
ROI: 30.39 14.63 14.06
ROE: 46.30 15.43 14.98

BRIEF-Sosei Group says $10 million milestone payment from Astrazeneca to Heptares

* Says Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, reported that it has been notified by its partner AstraZeneca that the first subject has been dosed with immuno-oncology candidate HTL1071 (AZD4635) in a Phase 1 clinical study, triggering a US$10 million payment from AstraZeneca

Jul 06 2016

BRIEF-Sosei Group says appoints Peter Bains as CEO

* Shinichi tamura, sosei founder and group chairman, president, ceo, appointed as representative executive officer and executive chairman

Jun 24 2016

BRIEF-Sosei Group appoints Peter Bains as CEO

* Says the co appointed Peter Bains as CEO, effective June 24

Jun 24 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : GlobalData
Provider : Reuters Investment Profile
Provider : Sadif Analytics Prime
Provider : Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.